Xolair is injected in patients 12 years of age and older who suffer from moderate to severe persistent allergic asthma caused by year round allergies. When paired with the patient’s current inhaled corticosteroids, Xolair reduces the number of daytime and nighttime asthma attacks in patients who suffer from two or more attacks a year, despite receiving treatment. Injections are administered every two or four weeks. The patient’s prescribed dosage will determine if one, two, or three injections are given per visit.